Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes

被引:108
作者
Otake, Y
Hsieh, F
Walle, T
机构
[1] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
D O I
10.1124/dmd.30.5.576
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a previous study, we used human liver microsomes for the first time to study cytochrome P450 (P450)-mediated oxidation of the flavonoid galangin. The combination of CYP1A2 and CYP2C9 produced a V-max/K-m value of 13.6 +/- 1.1 mul/min/mg of protein. In the present extended study, we determined glucuronidation rates for galangin with the same microsomes. Two major and one minor glucuronide were identified by liquid chromatography/mass spectrometry. The V-max/K-m values for the two major glucuronides conjugated in the 7- and 3-positions were 155 +/- 30 and 427 +/- 26 mul/min/mg of protein, thus, exceeding that of oxidation by 11 and 31 times, respectively. This highly efficient glucuronidation appeared to be catalyzed mainly by the UDP-glucuronosyltransferase (UGT)1A9 isoform but also by UGT1A1 and UGT2B15. Sulfation of galangin by the human liver cytosol, mediated mainly but not exclusively by sulfotransferase (SULT) 1A1, also appeared to be efficient. These conclusions were strongly supported by experiments using the S9 fraction of the human liver, in which all three metabolic pathways could be directly compared. When galangin metabolism was examined in fresh plated hepatocytes from six donors, glucuronidation clearly predominated followed by sulfation. Oxidation occurred only to a minor extent in two of the donors. This study for the first time establishes that glucuronidation and sulfation of galangin, and maybe other flavonoids, are more efficient than P450-mediated oxidation, clearly being the metabolic pathways of choice in intact cells and therefore likely also in vivo.
引用
收藏
页码:576 / 581
页数:6
相关论文
共 35 条
[1]  
ABE K, 1990, CHEM PHARM BULL, V38, P208, DOI 10.1248/cpb.38.208
[2]  
BOUTIN JA, 1993, DRUG METAB DISPOS, V21, P1157
[3]   HUMAN-LIVER PHENOL SULFOTRANSFERASE - ASSAY CONDITIONS, BIOCHEMICAL-PROPERTIES AND PARTIAL-PURIFICATION OF ISOZYMES OF THE THERMOSTABLE FORM [J].
CAMPBELL, NRC ;
VANLOON, JA ;
WEINSHILBOUM, RM .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (09) :1435-1446
[4]   Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells [J].
Ciolino, HP ;
Daschner, PJ ;
Wang, TTY ;
Yeh, GC .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (02) :197-206
[5]   CLONING AND EXPRESSION OF HUMAN LIVER DEHYDROEPIANDROSTERONE SULFOTRANSFERASE [J].
COMER, KA ;
FALANY, JL ;
FALANY, CN .
BIOCHEMICAL JOURNAL, 1993, 289 :233-240
[6]  
EBNER T, 1993, MOL PHARMACOL, V43, P649
[7]   Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers [J].
Erlund, I ;
Kosonen, T ;
Alfthan, G ;
Mäenpää, J ;
Perttunen, K ;
Kenraali, J ;
Parantainen, J ;
Aro, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (08) :545-553
[8]   BACTERIAL EXPRESSION AND CHARACTERIZATION OF A CDNA FOR HUMAN LIVER ESTROGEN SULFOTRANSFERASE [J].
FALANY, CN ;
KRASNYKH, V ;
FALANY, JL .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 52 (06) :529-539
[9]   Sulfation and sulfotransferases .3. Enzymology of human cytosolic sulfotransferases [J].
Falany, CN .
FASEB JOURNAL, 1997, 11 (04) :206-216
[10]  
Fisher MB, 2000, DRUG METAB DISPOS, V28, P560